Agency Information Collection Activities; New Information Collection Request: 391.41 CMV Driver Medication Form, 73871-73874 [2015-30134]
Download as PDF
Federal Register / Vol. 80, No. 227 / Wednesday, November 25, 2015 / Notices
a. Airman Certification Systems
Working Group
b. Aircraft Systems Information
Security/Protection Working Group
c. Air Traffic Controller Training
Working Group
d. Rotorcraft Occupant Protection
Working Group
e. Airworthiness Assurance Working
Group
f. Engine Harmonization Working
Group- Engine Endurance Testing
Requirements—Revision of Section
33.87
g. Flight Test Harmonization Working
Group—Phase 2 Tasking
h. Transport Airplane Metallic and
Composite Structures Working
Group—Transport Airplane
Damage-Tolerance and Fatigue
Evaluation
i. Transport Airplane Crashworthiness
and Ditching Evaluation Working
Group
4. New Tasks
a. Rotorcraft Bird Strike Working
Group
b. Additional Tasking for the Airman
Certification Systems Working
Group
c. Load Master Certification Working
Group
5. Status Report from the FAA
Attendance is open to the interested
public but limited to the space
available. Please confirm your
attendance with the person listed in the
tkelley on DSK3SPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT
section no later than December 10, 2015.
Please provide the following
information: full legal name, country of
citizenship, and name of your industry
association, or applicable affiliation. If
you are attending as a public citizen,
please indicate so.
For persons participating by
telephone, please contact the person
listed in the FOR FURTHER INFORMATION
CONTACT section by email or phone for
the teleconference call-in number and
passcode. Callers outside the
Washington metropolitan area are
responsible for paying long-distance
charges.
The public must arrange by December
10, 2015 to present oral statements at
the meeting. The public may present
written statements to the Aviation
Rulemaking Advisory Committee by
providing 25 copies to the Designated
Federal Officer, or by bringing the
copies to the meeting.
If you are in need of assistance or
require a reasonable accommodation for
this meeting, please contact the person
listed under the heading FOR FURTHER
INFORMATION CONTACT. Sign and oral
interpretation, as well as a listening
device, can be made available if
VerDate Sep<11>2014
19:15 Nov 24, 2015
Jkt 238001
requested 10 calendar days before the
meeting.
Issued in Washington, DC, on November
19, 2015.
Lirio Liu,
Designated Federal Officer, Aviation
Rulemaking Advisory Committee.
[FR Doc. 2015–29949 Filed 11–24–15; 8:45 am]
BILLING CODE 4910–13–P
DEPARTMENT OF TRANSPORTATION
Federal Highway Administration
Environmental Impact Statement:
Alexander, Pulaski, and Union
Counties, Illinois
Federal Highway
Administration (FHWA), DOT.
ACTION: Notice of intent.
AGENCY:
The FHWA is issuing this
notice to advise the public that an
Environmental Impact Statement (EIS)
will be prepared for the Shawnee
Parkway Project in Alexander, Pulaski,
and Union Counties, Illinois.
FOR FURTHER INFORMATION CONTACT:
Catherine A. Batey, Division
Administrator, Federal Highway
Administration, 3250 Executive Park
Drive, Springfield, Illinois 62703.
Phone: (217) 492–4600. Jeffrey L. Keirn,
PE., Deputy Director of Highways,
Region Five Engineer, Illinois
Department of Transportation, State
Transportation Building, 2801 W.
Murphysboro, P.O. Box 100,
Carbondale, Illinois 62903, (618) 549–
2171.
SUPPLEMENTARY INFORMATION: The
FHWA, in cooperation with Illinois
Department of Transportation, will
prepare an EIS for the Shawnee Parkway
project. The anticipated termini are the
intersection of Illinois Route 3 with
Illinois Route 146 and Interstate 57. The
project study area includes portions of
the following counties: Alexander,
Pulaski, and Union in Illinois. The
study area covers approximately 350
square miles.
The EIS for the Shawnee Parkway is
being conducted to evaluate the need for
improved transportation between the
anticipated termini within the study
area. The EIS will complete an analysis
of transportation alternative(s) in the
study area and evaluate environmental
impacts based on field investigations,
transportation studies, economic impact
studies, and cost analysis.
Alternatives assessed will seek to
avoid, minimize and mitigate impacts to
resources in the project area. In
accordance with IDOT policies, the
project is being developed using Context
SUMMARY:
PO 00000
Frm 00174
Fmt 4703
Sfmt 4703
73871
Sensitive Solutions (CSS) as a basis for
a stakeholder outreach program. A
scoping meeting will be held on
December 3, 2015.
A range of alternatives will be
developed and evaluated, including but
not limited to: Taking no action,
existing roadway improvements, and
new roadways on new location. The
Stakeholder Involvement Plan (SIP),
which will satisfy the 23 U.S.C. Section
139 requirements for a coordination
plan, will be developed to ensure that
a full range of issues related to this
proposed project are identified and
addressed. The SIP provides meaningful
opportunities for all stakeholders to
participate in defining transportation
issues and solutions for the study area.
Comments or questions concerning
this proposed action and the EIS are
invited from all interested parties and
should be directed to the FHWA at the
address provided above or the following
Web site: www.shawneeparkway.org.
A public hearing will be held after the
Draft EIS is published and made
available for public and agency review.
Public notice will be given of the time
and place of public meetings and
hearings.
The EIS will conclude with a Record
of Decision selecting either a no-build or
a preferred alternative.
(Catalog of Federal Domestic Assistance
Program Number 20.205, Highway Research,
Planning and Construction. The regulations
implementing Executive Order 12372
regarding intergovernmental consultation on
Federal programs and activities apply to this
program)
Issued on: November 19, 2015.
Catherine A. Batey,
Division Administrator, Federal Highway
Administration, Springfield, Illinois.
[FR Doc. 2015–30003 Filed 11–24–15; 8:45 am]
BILLING CODE 4910–22–P
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2015–0180]
Agency Information Collection
Activities; New Information Collection
Request: 391.41 CMV Driver
Medication Form
Federal Motor Carrier Safety
Administration (FMCSA), DOT.
ACTION: Notice and request for
comments.
AGENCY:
In accordance with the
Paperwork Reduction Act of 1995,
FMCSA announces its plan to submit
the Information Collection Request (ICR)
SUMMARY:
E:\FR\FM\25NON1.SGM
25NON1
tkelley on DSK3SPTVN1PROD with NOTICES
73872
Federal Register / Vol. 80, No. 227 / Wednesday, November 25, 2015 / Notices
described below to the Office of
Management and Budget (OMB) for its
review and approval and invites public
comment on the approval of a new ICR
titled, 391.41 CMV Driver Medication
Form. This ICR is voluntary and may be
utilized by medical examiners (MEs)
responsible for issuing Medical
Examiner’s Certificates (MECs) to
commercial motor vehicle (CMV)
drivers. MEs that choose to use this ICR
will do so in an effort to communicate
with treating healthcare professionals
who are responsible for prescribing
certain medications, so that the ME fully
understands the reasons the
medications have been prescribed. The
information obtained by the ME when
utilizing this ICR will assist the ME in
determining if the driver is medically
qualified under 49 CFR 391.41 and to
ensure that there are no disqualifying
medical conditions or underlying
medical conditions and prescribed
medications that could adversely affect
their safe driving ability or cause
incapacitation constituting a risk to the
public.
DATES: We must receive your comments
on or before January 25, 2016.
ADDRESSES: You may submit comments
identified by Federal Docket
Management System (FDMS) Docket
Number FMCSA–2015–0180 using any
of the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the online
instructions for submitting comments.
• Fax: 1–202–493–2251.
• Mail: Docket Services; U.S.
Department of Transportation, 1200
New Jersey Avenue SE., West Building,
Ground Floor, Room W12–140, 20590–
0001.
• Hand Delivery or Courier: West
Building, Ground Floor, Room W12–
140, 1200 New Jersey Avenue SE.,
Washington, DC, between 9 a.m. and 5
p.m. e.t., Monday through Friday,
except Federal holidays.
Instructions: All submissions must
include the Agency name and docket
number. For detailed instructions on
submitting comments and additional
information on the exemption process,
see the Public Participation heading
below. Note that all comments received
will be posted without change to https://
www.regulations.gov, including any
personal information provided. Please
see the Privacy Act heading below.
Docket: For access to the docket to
read background documents or
comments received, go to https://
www.regulations.gov, and follow the
online instructions for accessing the
dockets, or go to the street address listed
above.
VerDate Sep<11>2014
19:15 Nov 24, 2015
Jkt 238001
Privacy Act: In accordance with 5
U.S.C. 553(c), DOT solicits comments
from the public to better inform its
rulemaking process. DOT posts these
comments, without edit, including any
personal information the commenter
provides, to www.regulations.gov, as
described in the system of records
notice (DOT/ALL–14 FDMS), which can
be reviewed at www.dot.gov/privacy.
Public Participation: The Federal
eRulemaking Portal is available 24
hours each day, 365 days each year. You
can obtain electronic submission and
retrieval help and guidelines under the
‘‘help’’ section of the Federal
eRulemaking Portal Web site. If you
want us to notify you that we received
your comments, please include a selfaddressed, stamped envelope or
postcard, or print the acknowledgement
page that appears after submitting
comments online. Comments received
after the comment closing date will be
included in the docket and will be
considered to the extent practicable.
FOR FURTHER INFORMATION CONTACT:
Charles A. Horan III, Director, Office of
Carrier, Driver, and Vehicle, Safety
Standards, U.S. Department of
Transportation, Federal Motor Carrier
Safety Administration, West Building
6th Floor, 1200 New Jersey Avenue SE.,
Washington, DC 20590. Telephone:
202–366–2362; email
charles.horan@dot.gov.
SUPPLEMENTARY INFORMATION:
Background
The primary mission of the Federal
Motor Carrier Safety Administration
(FMCSA) is to reduce crashes, injuries,
and fatalities involving large trucks and
buses. The Secretary of Transportation
has delegated to FMCSA its
responsibility under 49 U.S.C. 31136
and 31502 to prescribe regulations that
ensure that CMVs are operated safely.
As part of this mission, the Agency’s
Medical Programs Division works to
ensure that CMV drivers engaged in
interstate commerce are physically
qualified and able to safely perform
their work.
Information used to determine and
certify driver medical fitness must be
collected in order for our highways to be
safe. FMCSA is the Federal government
agency authorized to require the
collection of this information and the
authorizing regulations are located at 49
CFR 390–399. FMCSA is required by
statute to establish standards for the
physical qualifications of drivers who
operate CMVs in interstate commerce
for non-excepted industries [49 U.S.C.
31136(a)(3) and 31502(b)]. The
regulations discussing this collection
PO 00000
Frm 00175
Fmt 4703
Sfmt 4703
are outlined in the Federal Motor
Carrier Safety Regulations (FMCSRs) at
49 CFR 390–399. FMCSRs at 49 CFR
391.41 set forth the physical
qualification standards that interstate
CMV drivers who are subject to part 391
must meet, with the exception of
commercial driver’s license/commercial
learner’s permit (CDL/CLP) drivers
transporting migrant workers (who must
meet the physical qualification
standards set forth in 49 CFR 398.3).
The FMCSRs covering driver physical
qualification records are found at 49
CFR 391.43, which specify that a
medical examination be performed on
CMV drivers subject to part 391 who
operate in interstate commerce. The
results of the examination shall be
recorded in accordance with the
requirements set forth in that section.
49 CFR 391.41(12) states that a person
is physically qualified to drive a CMV
if that person does not use any drug or
substance identified in 21 CFR 1308.11
Schedule I, an amphetamine, a narcotic,
or other habit-forming drug and does
not use any non-Schedule I drug or
substance that is identified in the other
Schedules in 21 part 1308 except when
the use is prescribed by a licensed
medical practitioner, as defined in
§ 382.107, who is familiar with the
driver’s medical history and has advised
the driver that the substance will not
adversely affect the driver’s ability to
safely operate a CMV.
In 2006, FMCSA’s Medical Review
Board (MRB) deliberated on the topic of
the use of Schedule II medications. The
MRB considered information provided
in a 2006 FMCSA sponsored Evidence
Report and a subsequent Medical Expert
Panel (MEP) to examine the relationship
between the licit use of a Schedule II
drug and the risk for a motor vehicle
crash. In 2013, FMCSA tasked the MRB
with updating the opinions and
recommendations of the 2006 Evidence
Report and MEP.
On September 10, 2013, the MRB and
Motor Carrier Safety Advisory
Committee (MCSAC) met jointly to hear
presentations on the licit use of
Schedule II medications and their
regulation, and on U.S. Department of
Transportation drug and alcohol testing
protocols. Subsequently, the committees
engaged in a discussion on the issue as
it applies to CMV drivers. On September
11, 2013, the MRB discussed the issue
in greater detail as its task to present a
letter report to the Agency relating to
CMV drivers and Schedule II
medication use and to develop a form
for MEs on the National Registry of
Certified Medical Examiners (National
Registry) to send to treating clinicians of
CMV drivers to expound on the use of
E:\FR\FM\25NON1.SGM
25NON1
tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 227 / Wednesday, November 25, 2015 / Notices
these medications by driver applicants.
On October 22, 2013, the MRB
submitted their recommendations to
FMCSA. A MEP convened to provide an
updated opinion on Schedule II Opioids
and Stimulants & CMV Crash Risk and
Driver Performance. The FMCSA
revised the task of the MRB instructing
them to review an updated evidence
report and the MEP opinion that was
furnished subsequent to its
deliberations on Schedule II Opioids
and Stimulants & CMV Crash Risk and
Driver Performance: Evidence Report
and Systematic Review. FMCSA
directed the MRB to consider this
report’s findings and confer with the
MCSAC on this topic during a joint
meeting in October 2014. The MRB met
in public meetings on July 29–30, 2014,
and developed Schedule II medication
recommendations. The MRB presented
these recommendations to the MCSAC
in a joint public meeting on October 27,
2014, where they were deliberated by
both committees. As a result, FMCSA’s
MRB and MCSAC provided joint
recommendations related to the use of
Schedule II medications by CMV
drivers. Because there is moderate
evidence to support the contention that
the licit use of opioids increases the risk
of motor vehicle crashes and impacts
indirect measures of driver performance
negatively, included was the
recommendation that FMCSA develop a
standardized medication questionnaire
to assist the certified ME when
reviewing prescription medications that
have been disclosed during the history
and physical examination for CMV
driver certification. The two advisory
groups recommended to FMCSA that
the standardized CMV driver
medication questionnaire be voluntary
and include the following information
and questions:
1. Questionnaire should be titled
391.41 CMV Driver Medication
Questionnaire.
2. Questionnaire should request the
following information:
a. Identifying name and date of birth
of the CMV driver.
b. Introductory paragraph stating
purpose of the CMV Driver Medication
Report.
c. Statements of 391.41(b)(12)
(Physical Qualifications of Drivers
relating to driver use of scheduled
substances) and The Driver’s Role, as
found in the Medical Examination
Report form found at the end of 49 CFR
391.43 (Medical Examination;
Certificate of Physical Examination).
d. Name, state of licensure, signature,
address and contact information of the
prescribing healthcare provider, as well
as the date the form was completed.
VerDate Sep<11>2014
19:15 Nov 24, 2015
Jkt 238001
e. Name, signature, date, address and
contact information of the certified ME.
3. Report should include the
following information:
a. 1—List all medications and dosages
that you have prescribed to the above
named individual.
b. 2—List any other medications and
dosages that you are aware have been
prescribed to the above named
individual by another treating
healthcare provider.
c. 3—What medical conditions are
being treated with these medications?
d. 4—It is my medical opinion that,
considering the mental and physical
requirements of operating a CMV and
with awareness of a CMV driver’s role
(consistent with The Driver’s Role
statement on page 2 of the form), I
believe my patient: (a) has no
medication side effects from
medication(s) that I prescribe that
would adversely affect the ability to
operate a CMV safely; and (2) has no
medical condition(s) that I am treating
with the above medication(s) that would
adversely affect the ability to operate a
CMV safely.
The public interest in, and right to
have, safe highways requires the
assurance that drivers of CMVs can
safely perform the increased physical
and mental demands of their duties.
FMCSA’s medical standards provide
this assurance by requiring drivers to be
examined and medically certified as
physically and mentally qualified to
drive.
The purpose for collecting this
information is to assist the ME in
determining if the driver is medically
qualified under 49 CFR 391.41 and to
ensure that there are no disqualifying
medical conditions that could adversely
affect their safe driving ability or cause
incapacitation constituting a risk to the
public. 49 CFR 391.41(12) states that a
person is physically qualified to drive a
CMV if that person does not use any
drug or substance identified in 21 CFR
1308.11 Schedule I, an amphetamine, a
narcotic, or other habit-forming drug
and does not use any non-Schedule I
drug or substance that is identified in
the other Schedules in 21 part 1308
except when the use is prescribed by a
licensed medical practitioner, as
defined in § 382.107, who is familiar
with the driver’s medical history and
has advised the driver that the
substance will not adversely affect the
driver’s ability to safely operate a CMV.
The use of this ICR is at the discretion
of the ME to facilitate communication
with treating healthcare professionals
who are responsible for prescribing
certain medications so that the ME fully
understands the reasons the
PO 00000
Frm 00176
Fmt 4703
Sfmt 4703
73873
medications have been prescribed. This
information will assist the ME in
determining whether the underlying
medical condition and the prescribed
medication will impact the driver’s safe
operation of a CMV. Therefore, there is
no required collection frequency.
The 391.41 CMV Driver Medication
Form will be available as a fillable pdf
or may be downloaded from the FMCSA
Web site. Prescribing healthcare
providers will also be able to fax or scan
and email the report to the certified ME.
Consistent with the OMB’s commitment
to minimizing respondents’
recordkeeping and paperwork burdens
and the increased use of secure
electronic modes of communication, the
Agency anticipates that approximately
50 percent of the 391.41 CMV Driver
Medication Forms will be transmitted
electronically.
The information collected from the
391.41 CMV Driver Medication Form,
will be used by the certified ME that
requested the completion of the form
and will become part of the CMV
driver’s record maintained by the
certified ME. Therefore, the information
will not be available to the public. The
FMCSRs covering driver physical
qualification records are found at 49
CFR 391.43, which specify that a
medical examination be performed on
CMV drivers subject to part 391 who
operate in interstate commerce. The
results of the examination shall be
recorded in accordance with the
requirements set forth in that section.
MEs are required to maintain records of
the CMV driver medical examinations
they conduct.
Title: 391.41 CMV Driver Medication
Form.
OMB Control Number: 2126–00XX.
Type of Request: New collection.
Respondents: Prescribing healthcare
professionals.
Estimated Number of Respondents:
1,082,200 (total number of prescribing
healthcare providers in the U.S.)
Estimated Time per Response: 8
minutes.
Expiration Date: N/A. This is a new
ICR.
Frequency of Response: Voluntary.
Estimated Total Annual Burden:
144,293 hours [1,082,200 responses × 8
minutes to complete response/60
minutes = 144,293].
Public Comments Invited: You are
asked to comment on any aspect of this
information collection, including: (1)
whether the proposed collection is
necessary for the performance of
FMCSA’s functions; (2) the accuracy of
the estimated burden; (3) ways for
FMCSA to enhance the quality,
usefulness, and clarity of the collected
E:\FR\FM\25NON1.SGM
25NON1
73874
Federal Register / Vol. 80, No. 227 / Wednesday, November 25, 2015 / Notices
information; and (4) ways that the
burden could be minimized without
reducing the quality of the collected
information. The agency will summarize
or include your comments in the request
for OMB’s clearance of this information
collection.
Issued under the authority of 49 CFR 1.87
on: Nov 6, 2015.
G. Kelly Regal,
Associate Administrator for Office of
Research and Information Technology.
[FR Doc. 2015–30134 Filed 11–24–15; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF TRANSPORTATION
Federal Railroad Administration
[Docket No. FRA 2015–0007–N–30]
Proposed Agency Information
Collection Activities; Comment
Request
Mr.
Robert Brogan, Regulatory Safety
Analysis Division, RRS–21, Federal
Railroad Administration, 1200 New
Jersey Ave. SE., Mail Stop 25,
Washington, DC 20590 (telephone: (202)
493–6292) or Ms. Kimberly Toone,
Office of Information Technology, RAD–
20, Federal Railroad Administration,
1200 New Jersey Ave. SE., Mail Stop 35,
Washington, DC 20590 (telephone: (202)
493–6132). (These telephone numbers
are not toll-free.)
SUPPLEMENTARY INFORMATION: The
Paperwork Reduction Act of 1995
(PRA), Public Law 104–13, sec. 2, 109
Stat. 163 (1995) (codified as revised at
44 U.S.C. 3501–3520), and its
implementing regulations, 5 CFR part
1320, require Federal agencies to
provide 60-days notice to the public for
comment on information collection
activities before seeking approval for
reinstatement or renewal by OMB. 44
U.S.C. 3506(c)(2)(A); 5 CFR 1320.8(d)(1),
1320.10(e)(1), 1320.12(a). Specifically,
FRA invites interested respondents to
comment on the following summary of
proposed information collection
activities regarding (i) whether the
information collection activities are
necessary for FRA to properly execute
its functions, including whether the
activities will have practical utility; (ii)
FOR FURTHER INFORMATION CONTACT:
Federal Railroad
Administration (FRA), Department of
Transportation.
ACTION: Notice and request for
comments.
AGENCY:
In accordance with the
Paperwork Reduction Act of 1995 and
its implementing regulations, the
Federal Railroad Administration (FRA)
hereby announces that it is seeking
renewal of the following currently
approved information collection
activities. Before submitting these
information collection requests (ICRs)
for clearance by the Office of
Management and Budget (OMB), FRA is
soliciting public comment on specific
aspects of the activities identified
below.
DATES: Comments must be received no
later than January 25, 2016.
ADDRESSES: Submit written comments
on any or all of the following proposed
activities by mail to either: Mr. Robert
Brogan, Office of Safety, Regulatory
Safety Analysis Division, RRS–21,
Federal Railroad Administration, 1200
New Jersey Ave. SE., Mail Stop 25,
Washington, DC 20590, or Ms. Kimberly
Toone, Office of Information
SUMMARY:
Technology, RAD–20, Federal Railroad
Administration, 1200 New Jersey Ave.
SE., Mail Stop 35, Washington, DC
20590. Commenters requesting FRA to
acknowledge receipt of their respective
comments must include a self-addressed
stamped postcard stating, ‘‘Comments
on OMB control number 2130–0525’’.
Alternatively, comments may be
transmitted via facsimile to (202) 493–
6216 or (202) 493–6497, or via email to
Mr. Brogan at Robert.Brogan@dot.gov, or
to Ms. Toone at Kim.Toone@dot.gov.
Please refer to the assigned OMB control
number in any correspondence
submitted. FRA will summarize
comments received in response to this
notice in a subsequent notice and
include them in its information
collection submission to OMB for
approval.
Respondent
universe
(manufacturers)
tkelley on DSK3SPTVN1PROD with NOTICES
CFR section
223.17—Identification of Equipped Locomotives,
Passenger Cars, and Caboose.
223.17—Appendix A:
—Requests for Glazing Certification ................
—Marking Individual Units of Glazing Material
—Testing New Material and Providing
Verification Data.
VerDate Sep<11>2014
19:15 Nov 24, 2015
Jkt 238001
PO 00000
the accuracy of FRA’s estimates of the
burden of the information collection
activities, including the validity of the
methodology and assumptions used to
determine the estimates; (iii) ways for
FRA to enhance the quality, utility, and
clarity of the information being
collected; and (iv) ways for FRA to
minimize the burden of information
collection activities on the public by
automated, electronic, mechanical, or
other technological collection
techniques or other forms of information
technology (e.g., permitting electronic
submission of responses). See 44 U.S.C.
3506(c)(2)(A)(I)–(iv); 5 CFR
1320.8(d)(1)(I)–(iv). FRA believes that
soliciting public comment will promote
its efforts to reduce the administrative
and paperwork burdens associated with
the collection of information mandated
by Federal regulations. In summary,
FRA reasons that comments received
will advance three objectives: (i) Reduce
reporting burdens; (ii) ensure that it
organizes information collection
requirements in a ‘‘user friendly’’ format
to improve the use of such information;
and (iii) accurately assess the resources
expended to retrieve and produce
information requested. See 44 U.S.C.
3501.
Below is a brief summary of the
currently approved ICRs that FRA will
submit for clearance by OMB as
required under the PRA:
Title: Certification of Glazing
Materials.
OMB Control Number: 2130–0525.
Abstract: The collection of
information is set forth under 49 CFR
part 223, which requires the
certification and permanent marking of
glazing materials by the manufacturer.
The manufacturer is also responsible for
making available test verification data to
railroads and FRA upon request.
Form Number(s): N/A.
Affected Public: Businesses.
Respondent Universe: States and
Railroads.
Frequency of Submission: On
occasion.
Respondent Universe: 5
Manufacturers.
Average time per
response
Total annual responses
Total annual
burden hours
4
15 minutes ......................
50
5
5
5
Frm 00177
200 stencilings or metal
plates.
10 requests ....................
25,000 pieces .................
1 test ..............................
15 minutes ......................
480 pieces per hour .......
14 hours .........................
3
52
14
Fmt 4703
Sfmt 4703
E:\FR\FM\25NON1.SGM
25NON1
Agencies
[Federal Register Volume 80, Number 227 (Wednesday, November 25, 2015)]
[Notices]
[Pages 73871-73874]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-30134]
-----------------------------------------------------------------------
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety Administration
[Docket No. FMCSA-2015-0180]
Agency Information Collection Activities; New Information
Collection Request: 391.41 CMV Driver Medication Form
AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.
ACTION: Notice and request for comments.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Paperwork Reduction Act of 1995, FMCSA
announces its plan to submit the Information Collection Request (ICR)
[[Page 73872]]
described below to the Office of Management and Budget (OMB) for its
review and approval and invites public comment on the approval of a new
ICR titled, 391.41 CMV Driver Medication Form. This ICR is voluntary
and may be utilized by medical examiners (MEs) responsible for issuing
Medical Examiner's Certificates (MECs) to commercial motor vehicle
(CMV) drivers. MEs that choose to use this ICR will do so in an effort
to communicate with treating healthcare professionals who are
responsible for prescribing certain medications, so that the ME fully
understands the reasons the medications have been prescribed. The
information obtained by the ME when utilizing this ICR will assist the
ME in determining if the driver is medically qualified under 49 CFR
391.41 and to ensure that there are no disqualifying medical conditions
or underlying medical conditions and prescribed medications that could
adversely affect their safe driving ability or cause incapacitation
constituting a risk to the public.
DATES: We must receive your comments on or before January 25, 2016.
ADDRESSES: You may submit comments identified by Federal Docket
Management System (FDMS) Docket Number FMCSA-2015-0180 using any of the
following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the online instructions for submitting comments.
Fax: 1-202-493-2251.
Mail: Docket Services; U.S. Department of Transportation,
1200 New Jersey Avenue SE., West Building, Ground Floor, Room W12-140,
20590-0001.
Hand Delivery or Courier: West Building, Ground Floor,
Room W12-140, 1200 New Jersey Avenue SE., Washington, DC, between 9
a.m. and 5 p.m. e.t., Monday through Friday, except Federal holidays.
Instructions: All submissions must include the Agency name and
docket number. For detailed instructions on submitting comments and
additional information on the exemption process, see the Public
Participation heading below. Note that all comments received will be
posted without change to https://www.regulations.gov, including any
personal information provided. Please see the Privacy Act heading
below.
Docket: For access to the docket to read background documents or
comments received, go to https://www.regulations.gov, and follow the
online instructions for accessing the dockets, or go to the street
address listed above.
Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits
comments from the public to better inform its rulemaking process. DOT
posts these comments, without edit, including any personal information
the commenter provides, to www.regulations.gov, as described in the
system of records notice (DOT/ALL-14 FDMS), which can be reviewed at
www.dot.gov/privacy.
Public Participation: The Federal eRulemaking Portal is available
24 hours each day, 365 days each year. You can obtain electronic
submission and retrieval help and guidelines under the ``help'' section
of the Federal eRulemaking Portal Web site. If you want us to notify
you that we received your comments, please include a self-addressed,
stamped envelope or postcard, or print the acknowledgement page that
appears after submitting comments online. Comments received after the
comment closing date will be included in the docket and will be
considered to the extent practicable.
FOR FURTHER INFORMATION CONTACT: Charles A. Horan III, Director, Office
of Carrier, Driver, and Vehicle, Safety Standards, U.S. Department of
Transportation, Federal Motor Carrier Safety Administration, West
Building 6th Floor, 1200 New Jersey Avenue SE., Washington, DC 20590.
Telephone: 202-366-2362; email charles.horan@dot.gov.
SUPPLEMENTARY INFORMATION:
Background
The primary mission of the Federal Motor Carrier Safety
Administration (FMCSA) is to reduce crashes, injuries, and fatalities
involving large trucks and buses. The Secretary of Transportation has
delegated to FMCSA its responsibility under 49 U.S.C. 31136 and 31502
to prescribe regulations that ensure that CMVs are operated safely. As
part of this mission, the Agency's Medical Programs Division works to
ensure that CMV drivers engaged in interstate commerce are physically
qualified and able to safely perform their work.
Information used to determine and certify driver medical fitness
must be collected in order for our highways to be safe. FMCSA is the
Federal government agency authorized to require the collection of this
information and the authorizing regulations are located at 49 CFR 390-
399. FMCSA is required by statute to establish standards for the
physical qualifications of drivers who operate CMVs in interstate
commerce for non-excepted industries [49 U.S.C. 31136(a)(3) and
31502(b)]. The regulations discussing this collection are outlined in
the Federal Motor Carrier Safety Regulations (FMCSRs) at 49 CFR 390-
399. FMCSRs at 49 CFR 391.41 set forth the physical qualification
standards that interstate CMV drivers who are subject to part 391 must
meet, with the exception of commercial driver's license/commercial
learner's permit (CDL/CLP) drivers transporting migrant workers (who
must meet the physical qualification standards set forth in 49 CFR
398.3). The FMCSRs covering driver physical qualification records are
found at 49 CFR 391.43, which specify that a medical examination be
performed on CMV drivers subject to part 391 who operate in interstate
commerce. The results of the examination shall be recorded in
accordance with the requirements set forth in that section.
49 CFR 391.41(12) states that a person is physically qualified to
drive a CMV if that person does not use any drug or substance
identified in 21 CFR 1308.11 Schedule I, an amphetamine, a narcotic, or
other habit-forming drug and does not use any non-Schedule I drug or
substance that is identified in the other Schedules in 21 part 1308
except when the use is prescribed by a licensed medical practitioner,
as defined in Sec. 382.107, who is familiar with the driver's medical
history and has advised the driver that the substance will not
adversely affect the driver's ability to safely operate a CMV.
In 2006, FMCSA's Medical Review Board (MRB) deliberated on the
topic of the use of Schedule II medications. The MRB considered
information provided in a 2006 FMCSA sponsored Evidence Report and a
subsequent Medical Expert Panel (MEP) to examine the relationship
between the licit use of a Schedule II drug and the risk for a motor
vehicle crash. In 2013, FMCSA tasked the MRB with updating the opinions
and recommendations of the 2006 Evidence Report and MEP.
On September 10, 2013, the MRB and Motor Carrier Safety Advisory
Committee (MCSAC) met jointly to hear presentations on the licit use of
Schedule II medications and their regulation, and on U.S. Department of
Transportation drug and alcohol testing protocols. Subsequently, the
committees engaged in a discussion on the issue as it applies to CMV
drivers. On September 11, 2013, the MRB discussed the issue in greater
detail as its task to present a letter report to the Agency relating to
CMV drivers and Schedule II medication use and to develop a form for
MEs on the National Registry of Certified Medical Examiners (National
Registry) to send to treating clinicians of CMV drivers to expound on
the use of
[[Page 73873]]
these medications by driver applicants. On October 22, 2013, the MRB
submitted their recommendations to FMCSA. A MEP convened to provide an
updated opinion on Schedule II Opioids and Stimulants & CMV Crash Risk
and Driver Performance. The FMCSA revised the task of the MRB
instructing them to review an updated evidence report and the MEP
opinion that was furnished subsequent to its deliberations on Schedule
II Opioids and Stimulants & CMV Crash Risk and Driver Performance:
Evidence Report and Systematic Review. FMCSA directed the MRB to
consider this report's findings and confer with the MCSAC on this topic
during a joint meeting in October 2014. The MRB met in public meetings
on July 29-30, 2014, and developed Schedule II medication
recommendations. The MRB presented these recommendations to the MCSAC
in a joint public meeting on October 27, 2014, where they were
deliberated by both committees. As a result, FMCSA's MRB and MCSAC
provided joint recommendations related to the use of Schedule II
medications by CMV drivers. Because there is moderate evidence to
support the contention that the licit use of opioids increases the risk
of motor vehicle crashes and impacts indirect measures of driver
performance negatively, included was the recommendation that FMCSA
develop a standardized medication questionnaire to assist the certified
ME when reviewing prescription medications that have been disclosed
during the history and physical examination for CMV driver
certification. The two advisory groups recommended to FMCSA that the
standardized CMV driver medication questionnaire be voluntary and
include the following information and questions:
1. Questionnaire should be titled 391.41 CMV Driver Medication
Questionnaire.
2. Questionnaire should request the following information:
a. Identifying name and date of birth of the CMV driver.
b. Introductory paragraph stating purpose of the CMV Driver
Medication Report.
c. Statements of 391.41(b)(12) (Physical Qualifications of Drivers
relating to driver use of scheduled substances) and The Driver's Role,
as found in the Medical Examination Report form found at the end of 49
CFR 391.43 (Medical Examination; Certificate of Physical Examination).
d. Name, state of licensure, signature, address and contact
information of the prescribing healthcare provider, as well as the date
the form was completed.
e. Name, signature, date, address and contact information of the
certified ME.
3. Report should include the following information:
a. 1--List all medications and dosages that you have prescribed to
the above named individual.
b. 2--List any other medications and dosages that you are aware
have been prescribed to the above named individual by another treating
healthcare provider.
c. 3--What medical conditions are being treated with these
medications?
d. 4--It is my medical opinion that, considering the mental and
physical requirements of operating a CMV and with awareness of a CMV
driver's role (consistent with The Driver's Role statement on page 2 of
the form), I believe my patient: (a) has no medication side effects
from medication(s) that I prescribe that would adversely affect the
ability to operate a CMV safely; and (2) has no medical condition(s)
that I am treating with the above medication(s) that would adversely
affect the ability to operate a CMV safely.
The public interest in, and right to have, safe highways requires
the assurance that drivers of CMVs can safely perform the increased
physical and mental demands of their duties. FMCSA's medical standards
provide this assurance by requiring drivers to be examined and
medically certified as physically and mentally qualified to drive.
The purpose for collecting this information is to assist the ME in
determining if the driver is medically qualified under 49 CFR 391.41
and to ensure that there are no disqualifying medical conditions that
could adversely affect their safe driving ability or cause
incapacitation constituting a risk to the public. 49 CFR 391.41(12)
states that a person is physically qualified to drive a CMV if that
person does not use any drug or substance identified in 21 CFR 1308.11
Schedule I, an amphetamine, a narcotic, or other habit-forming drug and
does not use any non-Schedule I drug or substance that is identified in
the other Schedules in 21 part 1308 except when the use is prescribed
by a licensed medical practitioner, as defined in Sec. 382.107, who is
familiar with the driver's medical history and has advised the driver
that the substance will not adversely affect the driver's ability to
safely operate a CMV.
The use of this ICR is at the discretion of the ME to facilitate
communication with treating healthcare professionals who are
responsible for prescribing certain medications so that the ME fully
understands the reasons the medications have been prescribed. This
information will assist the ME in determining whether the underlying
medical condition and the prescribed medication will impact the
driver's safe operation of a CMV. Therefore, there is no required
collection frequency.
The 391.41 CMV Driver Medication Form will be available as a
fillable pdf or may be downloaded from the FMCSA Web site. Prescribing
healthcare providers will also be able to fax or scan and email the
report to the certified ME. Consistent with the OMB's commitment to
minimizing respondents' recordkeeping and paperwork burdens and the
increased use of secure electronic modes of communication, the Agency
anticipates that approximately 50 percent of the 391.41 CMV Driver
Medication Forms will be transmitted electronically.
The information collected from the 391.41 CMV Driver Medication
Form, will be used by the certified ME that requested the completion of
the form and will become part of the CMV driver's record maintained by
the certified ME. Therefore, the information will not be available to
the public. The FMCSRs covering driver physical qualification records
are found at 49 CFR 391.43, which specify that a medical examination be
performed on CMV drivers subject to part 391 who operate in interstate
commerce. The results of the examination shall be recorded in
accordance with the requirements set forth in that section. MEs are
required to maintain records of the CMV driver medical examinations
they conduct.
Title: 391.41 CMV Driver Medication Form.
OMB Control Number: 2126-00XX.
Type of Request: New collection.
Respondents: Prescribing healthcare professionals.
Estimated Number of Respondents: 1,082,200 (total number of
prescribing healthcare providers in the U.S.)
Estimated Time per Response: 8 minutes.
Expiration Date: N/A. This is a new ICR.
Frequency of Response: Voluntary.
Estimated Total Annual Burden: 144,293 hours [1,082,200 responses x
8 minutes to complete response/60 minutes = 144,293].
Public Comments Invited: You are asked to comment on any aspect of
this information collection, including: (1) whether the proposed
collection is necessary for the performance of FMCSA's functions; (2)
the accuracy of the estimated burden; (3) ways for FMCSA to enhance the
quality, usefulness, and clarity of the collected
[[Page 73874]]
information; and (4) ways that the burden could be minimized without
reducing the quality of the collected information. The agency will
summarize or include your comments in the request for OMB's clearance
of this information collection.
Issued under the authority of 49 CFR 1.87 on: Nov 6, 2015.
G. Kelly Regal,
Associate Administrator for Office of Research and Information
Technology.
[FR Doc. 2015-30134 Filed 11-24-15; 8:45 am]
BILLING CODE 4910-EX-P